A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2015
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 18 Aug 2015 Planned initiation date changed from 1 Jun 2015 to 1 Sep 2015.
- 12 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.